Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Astellas Pharma and its Canadian affiliate Astellas Pharma Canada have sued Sandoz Canada in the Federal Court of Canada on 13 July 2011.
Subscribe to our email newsletter
Astellas has filed a notice of application to the Patented Medicine (Notice of Compliance) Regulations in Canada against Sandoz Canada related to the filing of an abbreviated new drug submission (ANDS) by Sandoz for the Prograf, which is the generic version of Astellas tacrolimus hydrate.
Developed by Astellas, tacrolimus is used together with other medicines for preventing body from rejecting a heart, liver or kidney transplant.
In its application, Astellas has requested the Canadian Minister of Health not to issue marketing approval to Sandoz prior to the expiration of its patent for tacrolimus hydrate.